ARTICLE | Deals
If fulfilled, CVR tied to pipeline programs would drive deal’s value even further
By Paul Bonanos, Director of Biopharma Intelligence
November 26, 2024 9:40 PM UTC
Roche’s high-premium takeout of Poseida placed a higher value on the CAR T developer than the public markets had bestowed in the past three years — and the deal’s size could grow if all three components of a CVR are fulfilled.
The deal by Roche (SIX:ROG; OTCQX:RHHBY) to acquire Poseida Therapeutics Inc. (NASDAQ:PSTX) for $9 per share, or about $1 billion, came at a premium of 215% over Poseida’s closing price of $2.86 on Monday. That’s much higher than typical premiums seen in biotech takeouts in recent years; although a handful have exceeded 200%, most have been in the high double-digits, roughly 50-100%…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654327/roche-rewards-poseida-s-shareholders-with-high-premium-in-1b-takeout